Prevalence of red cell alloantibodies in transfusion-dependent thalassemia: a cross-sectional study from Bangladesh
DOI:
https://doi.org/10.18203/2320-6012.ijrms20260601Keywords:
Alloimmunization, Stem cell transplantation, ThalassemiaAbstract
Background: Red cell alloimmunization is a significant transfusion complication in transfusion-dependent thalassemia (TDT) patients, complicating subsequent transfusions and hematopoietic stem cell transplantation (HSCT). The aim of the study was to determine the prevalence of red cell alloimmunization among TDT patients seen at a specialized center in Bangladesh, define the spectrum of clinically significant alloantibodies, and identify risk factors with special reference to transplant-eligible patients.
Methods: This was a cross-sectional study conducted at Islamic Bank Hospital and Cardiac Centre, Dhaka, Bangladesh from February 2023 to April 2024, among 860 transfusion-dependent thalassemia patients. A three-cell screening panel was used to screen red cell antibodies in all the samples. Screen-positive samples were detected by a fourteen-cell identification panel on a fully automated immunohematology analyzer. Clinical and laboratory data, including hemoglobin, serum ferritin, age, sex, and thalassemia subtype, were collected. Modified Poisson regression with robust standard errors was employed to determine risk factors.
Results: Total red cell alloimmunization prevalence was 9.8% (95% CI: 8.0-11.9%), and all of the detected antibodies were clinically significant. Of alloimmunized patients, 45.2% were ≤16 years (transplant-eligible age). The most frequent were anti-E (33.3%), anti-c (21.4%), anti-D (16.7%), and anti-C (11.9%) from the Rh system, and anti-Kpa (9.5%) and anti-Kpb (7.1%) from the Kell system. Risk factors were age ≥16 years (aPR 1.68, 95% CI: 1.13-2.52) and β-thalassemia major subtype compared with HbE/β-thalassemia (aPR 0.31, 95% CI: 0.20-0.47).
Conclusions: Red cell alloimmunization occurs in nearly 10% of TDT patients in Bangladesh and has significant implications for transplant-eligible patients. Extended phenotyping and prophylactic matching practices need to be implemented, particularly among high-risk groups, to optimise transfusion management and transplant readiness.
Metrics
References
Weatherall DJ, Clegg JB. Inherited haemoglobin disorders: an increasing global health problem. Bull World Health Organ. 2001;79(8):704-12.
Hossain MS, Raheem E, Sultana TA, Ferdous S, Nahar N, Islam S, et al. Thalassemias in South Asia: clinical lessons learnt from Bangladesh. Orphanet J Rare Dis. 2017;12(1):93. DOI: https://doi.org/10.1186/s13023-017-0643-z
Choudhry VP. Thalassemia minor and major: current management. Indian J Pediatr. 2017;84(8):607-11. DOI: https://doi.org/10.1007/s12098-017-2325-1
Thompson AA, Cunningham MJ, Singer ST, Neufeld EJ, Vichinsky E, Yamashita R, et al. Red cell alloimmunization in a diverse population of transfused patients with thalassaemia. Br J Hematol. 2011;153(1):121-8. DOI: https://doi.org/10.1111/j.1365-2141.2011.08576.x
Matteocci A, Pierelli L. Red blood cell alloimmunization in sickle cell disease and in thalassaemia: current status, future perspectives and potential role of molecular typing. Vox Sanguinis. 2014;106(3):197-208.
Borgna-Pignatti C, Marsella M. Iron chelation in thalassemia major. Clin Ther. 2015;37(12):2866-77. DOI: https://doi.org/10.1016/j.clinthera.2015.10.001
Pahuja S, Pujani M, Gupta SK, Chandra J, Jain M. Alloimmunization and red cell autoimmunization in multitransfused thalassemics of Indian origin. Hematology. 2010;15(3):174-7. DOI: https://doi.org/10.1179/102453309X12583347114013
Singer ST, Wu V, Mignacca R, Kuypers FA, Morel P, Vichinsky EP. Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly Asian descent. Blood J Am Soc Hematol. 2000;96(10):3369-73. DOI: https://doi.org/10.1182/blood.V96.10.3369.h8003369_3369_3373
Ameen R, Al‐Shemmari S, Al‐Humood S, Chowdhury RI, Al‐Eyaadi O, Al‐Bashir A. RBC alloimmunization and autoimmunization among transfusion‐dependent Arab thalassemia patients. Transfusion. 2003;43(11):1604-10. DOI: https://doi.org/10.1046/j.1537-2995.2003.00549.x
Sadeghian MH, Keramati MR, Badiei Z, Ravarian M, Ayatollahi H, Rafatpanah H, et al. Alloimmunization among transfusion-dependent thalassemia patients. Asian J Transfus Sci. 2009;3(2):95-8. DOI: https://doi.org/10.4103/0973-6247.53884
Spanos TH, Karageorga M, Ladis V, Peristeri J, Hatziliami A, Kattamis C. Red cell alloantibodies in patients with thalassemia. Vox Sanguinis. 1990;58(1):50-5. DOI: https://doi.org/10.1111/j.1423-0410.1990.tb02055.x
Almorish MA, Al-Absi B, Elkhalifa AM, Alhamidi AH, Abdelrahman M. Red blood cell alloimmunization in blood transfusion-dependent β thalassemia major patients in Sana’a City-Yemen. Sci Rep. 2024;14(1):1005. DOI: https://doi.org/10.1038/s41598-024-51561-2
El-Beshlawy A, Salama AA, El-Masry MR, El Husseiny NM, Abdelhameed AM. A study of red blood cell alloimmunization and autoimmunization among 200 multitransfused Egyptian β thalassemia patients. Sci Rep. 2020;10(1):21079. DOI: https://doi.org/10.1038/s41598-020-78333-y
Matteocci A, Pierelli L. Red blood cell alloimmunization in sickle cell disease and in thalassaemia: current status, future perspectives and potential role of molecular typing. Vox Sanguinis. 2014;106(3):197-208. DOI: https://doi.org/10.1111/vox.12086
Chou ST, Liem RI, Thompson AA. Challenges of alloimmunization in patients with haemoglobinopathies. Br J Hematol. 2012;159(4):394-404. DOI: https://doi.org/10.1111/bjh.12061
Westhoff CM. Blood group genotyping. Blood J Am Soc Hematol. 2019;133(17):1814-20. DOI: https://doi.org/10.1182/blood-2018-11-833954
Schonewille H, Van De Watering LM, Brand A. Additional red blood cell alloantibodies after blood transfusions in a nonhematologic alloimmunized patient cohort: is it time to take precautionary measures? Transfusion. 2006;46(4):630-5. DOI: https://doi.org/10.1111/j.1537-2995.2006.00764.x
Weatherall DJ. The inherited diseases of hemoglobin are an emerging global health burden. Blood J Am Soc Hematol. 2010;115(22):4331-6. DOI: https://doi.org/10.1182/blood-2010-01-251348
De Sanctis V, Kattamis C, Canatan D, Soliman AT, Elsedfy H, Karimi M, et al. β-thalassemia distribution in the old world: an ancient disease seen from a historical standpoint. Mediter J Hematol Infect Dis. 2017;9(1):e2017018. DOI: https://doi.org/10.4084/mjhid.2017.018
Hongeng S, Pakakasama S, Chuansumrit A, Sirachainan N, Kitpoka P, Udomsubpayakul U, et al. Outcomes of transplantation with related-and unrelated-donor stem cells in children with severe thalassemia. Biol Blood Marrow Transplant. 2006;12(6):683-7. DOI: https://doi.org/10.1016/j.bbmt.2006.02.008
Thompson AA, Walters MC, Kwiatkowski J, Rasko JE, Ribeil JA, Hongeng S, et al. Gene therapy in patients with transfusion-dependent β-thalassemia. N Engl J Med. 2018;378(16):1479-93. DOI: https://doi.org/10.1056/NEJMoa1705342
Al-Agha AE, Bawahab NS, Nagadi SA, Alghamdi SA, Felemban DA, Milyani AA. Endocrinopathies complicating transfusion-dependent hemoglobinopathy. Saudi Med J. 2020;41(2):138. DOI: https://doi.org/10.15537/smj.2020.2.24845
Vichinsky EP, Luban NL, Wright E, Olivieri N, Driscoll C, Pegelow CH, et al. Prospective RBC phenotype matching in a stroke‐prevention trial in sickle cell anemia: a multicenter transfusion trial. Transfusion. 2001;41(9):1086-92. DOI: https://doi.org/10.1046/j.1537-2995.2001.41091086.x
Downloads
Published
How to Cite
Issue
Section
